Diagnosis and treatment of malignant neoplasms of the upper gastrointestinal tract (Electronic educational course, 36 hours.)
In the last decade, there has been an increase in the incidence of cancer in the upper gastrointestinal tract. For example, stomach cancer is one of the most common malignant diseases, occupies the 5th place in the structure of oncological diseases in the world and the 2nd place in Russia and is on the 3rd place in terms of mortality among oncological diseases, more than 70% of patients, as a rule, are detected with the III-IV stages of the disease. Due to the development of modern diagnostic methods, screening can reduce mortality from this disease and increase survival, but the results remain unsatisfactory - the 5-year survival rate ranges from 15 to 30% in different countries. Currently, the main method of treating stomach cancer is surgical, - there is a significant improvement in the results of surgical treatment: a decrease in the frequency of postoperative complications and mortality. We will tell you about the peculiarities of surgical treatment in our course.
Esophageal cancer is one of the most aggressive among malignant neoplasms, it is the 6th most common in the world. A sufficiently effective treatment has not yet been found, the results of chemoradiotherapy remain unsatisfactory, and from the point of view of the genetics of the pathogenesis of the disease remains a mystery. Currently, the use of a modern arsenal of diagnostic tools makes it possible to accurately assess the prevalence of a tumor.
Many studies are being conducted to explore the possibilities and improve the effectiveness of molecular and pharmacological treatment, but today the main method of treating the disease remains surgery.
Cancer of the oral cavity, various parts of the pharynx and larynx, and the paranasal sinuses, due to their anatomical location, can spread to the structures of the base of the skull with invasion of both bone structures and the shell and, less often, the substance of the brain. Risk factors for the development of these tumors are the use of tobacco, alcohol, as well as infection with HPV type 16 and the Epstein – Barr virus.
Liver tumors play an important role in oncology. Every third patient with a first-time diagnosis of cancer already has distant liver metastases. In most cases, malignant tumors are detected in patients who suffer from other diseases for a long time, involving the hepatic parenchyma in the pathological process with the development of chronic inflammation.
Pancreatic cancer takes the 10th place in morbidity and the 4th place in mortality. The one - year survival rate is 26%; the 5-year survival rate is about 6%. If a tumor is detected at an early stage, its surgical removal is possible, and the 5-year survival rate increases to 23%.
Gastrointestinal stromal tumors are relatively rare —10-15 cases per 1 million population. Most often, tumors are localized in the stomach and small intestine, as well as in the duodenum and rectum. Rare localizations — esophagus, colon, large omentum, mesentery, retroperitoneal space. The key mechanism of tumor development is a mutation in the c-kit gene (80 %) or PDGFRA (10 %). Progression is manifested by metastases in the liver and / or peritoneum. Therapy with tyrosine kinase inhibitors is the main method of treatment of metastatic disease, chemotherapy is ineffective.
As part of the course, we will analyze:
1. Issues of epidemiology, risk factors, diagnosis, staging of stomach and esophageal cancer, head and neck tumors, liver tumors, pancreatic cancer and non-endocrine tumors.
2. We will study the features of drug therapy and surgical treatment of various forms of cancer of the stomach and esophagus, liver tumors, pancreatic cancer and non-endocrine tumors.
3. General principles of diagnosis and treatment of neuroendocrine tumors
The purpose of the program is to improve the knowledge of specialists on the diagnosis and treatment of stomach and esophageal cancer, liver tumors, pancreatic cancer and non-endocrine tumors. Informing specialists about the use of modern possibilities of chemotherapy, hormone therapy, biological therapy, radiation therapy, combined and complex methods of treatment and criteria for evaluating the effectiveness of these methods.
A special feature of the course is distance learning by means of electronic educational environment with the use of interactive communication technologies.
As a result of the course, the student must acquire or update general and special knowledge and skills in the diagnosis, early detection and treatment of diseases of oncological and gastroenterological profiles.
Students who have completed their training and successfully passed the final certification in the form of a test receive a certificate of advanced training.
Category of trainees: medical specialists in the following areas of training: "Oncology", "Gastroenterology", "Surgery", " General Medical practice (family medicine)", "Medical business".
Form of study: part-time.
Duration of training: 36 academic hours.
Speakers of the advanced training course:
- Valery V. Breder-MD, oncologist, chemotherapist, N. N. Blokhin National Research Medical Center of Oncology, Ministry of Health of the Russian Federation;
- Vinnitskaya Elena Vladimirovna-MD, Head of the Research Department of Hepatology, gastroenterologist, hepatologist of the State Medical Institution of the Moscow State Scientific Research Center named after A. S. Loginov DZM;
- Ignatova Ekaterina Olegovna-Candidate of Medical Sciences, Associate Professor of the Department of Clinical Pharmacology and Chemotherapy of the N. N. Blokhin National Research Center of Oncology of the Ministry of Health of the Russian Federation;
- Roman E. Izrailov-MD, Professor, Head of the Department of High-Tech Surgery and Surgical Endoscopy of the State Medical Institution of the Moscow State Medical Center named after A. S. Loginov DZM;
- Vladislav Kosyrev-MD, Doctor of the Highest category, oncologist, surgeon, N. N. Blokhin National Research Medical Center of Oncology, Ministry of Health of the Russian Federation;
- Kropotov Mikhail Alekseevich-oncologist, state budgetary institution of health care of the city of Moscow " Moscow Clinical Scientific and Practical Center named after A. S. Loginov of the Department of Health of the City of Moscow "(GBUZ MCSC named after A. S. Loginov DZM);
- Alla A. Markovich-Candidate of Medical Sciences, Senior Researcher at the N. N. Blokhin National Research Center of Oncology, Ministry of Health of the Russian Federation;
- Pavlov Rostislav Vladimirovich-Oncologist-surgeon, Head of the Department of the operating unit of the N. I. Pirogov KVMT;
- Ivan Nikolaevich Baudiev-Candidate of Medical Sciences, oncologist, Surgeon, N. N. Blokhin National Research Medical Center of Oncology, Ministry of Health of the Russian Federation;
- Ilya A. Pokataev-Candidate of Medical Sciences, oncologist, chemotherapist, Researcher of the Department of Clinical Pharmacology and Chemotherapy of the Research Institute of Clinical Oncology of the N. N. Blokhin National Research Center of Oncology of the Ministry of Health of the Russian Federation;
- Alexey A. Tryakin-MD, Head of the day hospital for oncological profile, oncologist of the State Medical Institution of the Moscow State Medical Research Center named after A. S. Loginov DZM;
- Ilya Feidorov-Researcher at the Center for Endocrine and Metabolic Surgery, Doctor-surgeon;
- Darya Filonenko-Candidate of Medical Sciences, oncologist, N. N. Blokhin National Research Medical Center of Oncology, Ministry of Health of the Russian Federation.